New cocktail aims to stall ovarian cancer

NCT ID NCT03737643

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This Phase 3 trial tests whether adding durvalumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and bevacizumab can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. About 1,400 participants are involved. The study compares the new combination against standard treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: durvalumab, bevacizumab, olaparib, carboplatin, paclitaxel
What this could lead to: If successful, this combination could offer a new standard treatment that delays cancer progression in advanced ovarian cancer patients.
What could go wrong: This is a large Phase 3 trial, but results are not yet final. The added drugs may increase side effects without improving outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,407 people

The number who actually took part.

Started

Jan 2019

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 130 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: Female patients with newly diagnosed, histologically confirmed, advanced (Stage III-IV) high grade epithelial ovarian cancer including high grade serious, high grade endometriod, clear cell ovarian cancer or carcinosarcoma, primary peritoneal cancer and / or fallopian-tube cancer * Patients must be aged ≥18 years of age. For patients enrolled in Japan that are aged \<20 year * All patients should be candidates for cytoreductive surgery either: upfront primary surgery OR plan to undergo chemotherapy with interval debulking surgery * Evidence of presence or absence of BRCA1/2 mutation in tumour tissue * Mandatory provision of tumour sample for centralised tBRCA testing * ECOG performance status 0-1 * Patients must have preserved organ and bone marrow function * Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test Key Exclusion Criteria: Non-epithelial ovarian cancer, borderline tumors, low grade epithelial tumors or mucinous histology * Prior systemic anti-cancer therapy for ovarian cancer * Inability to determine the presence or absence of a deleterious or suspected deleterious BRCA mutation * Prior treatment with PARP inhibitor or immune mediated therapy * Planned intraperitoneal cytotoxic chemotherapy * Active or prior documented autoimmune or inflammatory disorders * Patients considered a poor medical risk due to a serious, uncontrolled intercurrent illness * Clinically significant cardiovascular disease * Patients with known brain metastases * History of another primary malignancy except for: * Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study treatment and of low potential risk for recurrence (patients who have received prior adjuvant chemotherapy for early stage breast cancer may be eligible, provided that it was completed ≥3 years prior to registration, and that the patient remains free of recurrent or metastatic disease) * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease * Endometrial cancer FIGO Stage IA, Grade 1 or Grade 2 * Persistent toxicities CTCAE Grade \>2 caused by previous cancer therapy * Patients with a known hypersensitivity to olaparib, durvalumab or any of the excipients of these products and to the combination/comparator agents * Breast feeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced high-grade epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced ovarian cancer

Contacts and locations

Locations

Research Site

Foothill Ranch, California, 92610, United States
Research Site

Los Angeles, California, 90095, United States
Research Site

Orange, California, 92868-3298, United States
Research Site

San Francisco, California, 94158, United States
Research Site

Tampa, Florida, 33612, United States
Research Site

Augusta, Georgia, 30912, United States
Research Site

Hinsdale, Illinois, 60521, United States
Research Site

Indianapolis, Indiana, 46202, United States
Research Site

Towson, Maryland, 21204, United States
Research Site

Detroit, Michigan, 48202, United States
Research Site

Springfield, Missouri, 65807, United States
Research Site

Middletown, New Jersey, 07748, United States
Research Site

Montvale, New Jersey, 07645, United States
Research Site

Albany, New York, 12208, United States
Research Site

New York, New York, 10065, United States
Research Site

Uniondale, New York, 11553, United States
Research Site

Durham, North Carolina, 27710, United States
Research Site

Cleveland, Ohio, 44195, United States
Research Site

Dayton, Ohio, 45429, United States
Research Site

Hilliard, Ohio, 43026, United States
Research Site

Tulsa, Oklahoma, 74134, United States
Research Site

Lancaster, Pennsylvania, 17601, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Philadelphia, Pennsylvania, 19107-5097, United States
Research Site

Pittsburgh, Pennsylvania, 15224, United States
Research Site

Salt Lake City, Utah, 84112, United States
Research Site

Graz, 8036, Austria
Research Site

Innsbruck, 6020, Austria
Research Site

Linz, 4020, Austria
Research Site

Vienna, 1090, Austria
Research Site

Aalst, 9300, Belgium
Research Site

Leuven, 3000, Belgium
Research Site

Namur, 5000, Belgium
Research Site

Ostend, 8400, Belgium
Research Site

Sint-Niklaas, 9100, Belgium
Research Site

Barretos, 14784-400, Brazil
Research Site

Florianópolis, 88034-000, Brazil
Research Site

Fortaleza, 60810-180, Brazil
Research Site

Londrina, 86015-520, Brazil
Research Site

Porto Alegre, 90020-090, Brazil
Research Site

Porto Alegre, 90110-270, Brazil
Research Site

Rio de Janeiro, 20220-410, Brazil
Research Site

São Paulo, 01317-000, Brazil
Research Site

São Paulo, 04014-002, Brazil
Research Site

Burgas, 8000, Bulgaria
Research Site

Plovdiv, 4004, Bulgaria
Research Site

Sofia, 1330, Bulgaria
Research Site

Varna, 9000, Bulgaria
Research Site

Calgary, Alberta, T2N 5G2, Canada
Research Site

Barrie, Ontario, L4M 6M2, Canada
Research Site

Greater Sudbury, Ontario, P3E 5J1, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Montreal, Quebec, H2X 3E4, Canada
Research Site

Montreal, Quebec, H3T 1E2, Canada
Research Site

Montreal, Quebec, H4A 3J1, Canada
Research Site

Québec, Quebec, G1J 1Z4, Canada
Research Site

Rimouski, Quebec, G5L 5T1, Canada
Research Site

Beijing, 100026, China
Research Site

Beijing, CN-100730, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 430033, China
Research Site

Chengdu, 610041, China
Research Site

Chongqing, 400030, China
Research Site

Dalian, 116001, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510080, China
Research Site

Hangzhou, 310009, China
Research Site

Hangzhou, 310022, China
Research Site

Harbin, 150081, China
Research Site

Hefei, 230031, China
Research Site

Jinhua, 321099, China
Research Site

Kunming, 650118, China
Research Site

Lanzhou, 730030, China
Research Site

Luzhou, 646099, China
Research Site

Nanchong, 637000, China
Research Site

Nanjing, 2100008, China
Research Site

Nanning, 530021, China
Research Site

Nantong, 226361, China
Research Site

Shanghai, 200011, China
Research Site

Shanghai, 200032, China
Research Site

Wuhan, 430030, China
Research Site

Wuhan, 430060, China
Research Site

Xi'an, 710061, China
Research Site

Zhengzhou, 450002, China
Research Site

Zhengzhou, 450008, China
Research Site

Zhuhai, 519099, China
Research Site

Aalborg, 9000, Denmark
Research Site

Aarhus N, 8200, Denmark
Research Site

Odense, 5000, Denmark
Research Site

Roskilde, 4000, Denmark
Research Site

Vejle, 7100, Denmark
Research Site

Kuopio, 70210, Finland
Research Site

Oulu, 90029, Finland
Research Site

Turku, 20521, Finland
Research Site

Besançon, 25000, France
Research Site

Bordeaux, 33076, France
Research Site

Limoges, 87042, France
Research Site

Lyon, 69373, France
Research Site

Marseille, 13273, France
Research Site

Nantes, 44202, France
Research Site

Paris, 75012, France
Research Site

Paris, 75015, France
Research Site

Paris, 75674, France
Research Site

Saint-Herblain, 44805, France
Research Site

Vandœuvre-lès-Nancy, 54519, France
Research Site

Bad Homburg, 61352, Germany
Research Site

Berlin, 10117, Germany
Research Site

Bielefeld, 33604, Germany
Research Site

Bonn, 53105, Germany
Research Site

Brandenburg, 14770, Germany
Research Site

Cologne, 50935, Germany
Research Site

Dresden, 1307, Germany
Research Site

Düsseldorf, 40489, Germany
Research Site

Essen, 45136, Germany
Research Site

Essen, 45147, Germany
Research Site

Esslingen am Neckar, 73730, Germany
Research Site

Frankfurt, 60590, Germany
Research Site

Freiburg im Breisgau, 79106, Germany
Research Site

Fürth, 90766, Germany
Research Site

Greifswald, 17475, Germany
Research Site

Gütersloh, 33332, Germany
Research Site

Hamburg, 20246, Germany
Research Site

Hamburg, 20357, Germany
Research Site

Hamburg, 22457, Germany
Research Site

Hanover, 30177, Germany
Research Site

Hanover, 30625, Germany
Research Site

Jena, 07747, Germany
Research Site

Karlsruhe, 76133, Germany
Research Site

Karlsruhe, 76135, Germany
Research Site

Kassel, 34125, Germany
Research Site

Kiel, 24105, Germany
Research Site

Leipzig, 04103, Germany
Research Site

Ludwigsburg, 71640, Germany
Research Site

Lübeck, 23538, Germany
Research Site

Mainz, 55131, Germany
Research Site

Mannheim, 68167, Germany
Research Site

München, 81377, Germany
Research Site

Offenbach, 63069, Germany
Research Site

Oldenburg, 26133, Germany
Research Site

Rosenheim, 83022, Germany
Research Site

Rostock, 18057, Germany
Research Site

Saalfeld, 07318, Germany
Research Site

Schweinfurt, 97422, Germany
Research Site

Tübingen, 72016, Germany
Research Site

Ulm, 89075, Germany
Research Site

Worms, 67550, Germany
Research Site

Budapest, 1062, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Debrecen, 4032, Hungary
Research Site

Győr, 9024, Hungary
Research Site

Kaposvár, 7400, Hungary
Research Site

Szeged, 6725, Hungary
Research Site

Zalaegerszeg, 8900, Hungary
Research Site

Brescia, 25123, Italy
Research Site

Lecce, 73100, Italy
Research Site

Lecco, 23900, Italy
Research Site

Milan, 20132, Italy
Research Site

Milan, 20141, Italy
Research Site

Mirano, 30035, Italy
Research Site

Naples, 80131, Italy
Research Site

Reggio Calabria, 89100, Italy
Research Site

Reggio Emilia, 42100, Italy
Research Site

Roma, 00168, Italy
Research Site

Torino, 10126, Italy
Research Site

Torino, 10128, Italy
Research Site

Fukuoka, 811-1395, Japan
Research Site

Kashiwa-shi, 277-8567, Japan
Research Site

Kobe, 650-0047, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Kurume-shi, 830-0011, Japan
Research Site

Kyoto, 606-8507, Japan
Research Site

Minatoku, 105-8471, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Niigata, 951-8520, Japan
Research Site

Okayama, 700-8558, Japan
Research Site

Sapporo, 003-0804, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Shinjuku-ku, 160-8582, Japan
Research Site

Sunto-gun, 411-8777, Japan
Research Site

Toyoake-shi, 470-1192, Japan
Research Site

Bellavista, CALLAO 2, Peru
Research Site

La Libertad, 13013, Peru
Research Site

Lima, LIMA 31, Peru
Research Site

Lima, Lima 32, Peru
Research Site

Lima, LIMA 34, Peru
Research Site

Lima, LIMA 41, Peru
Research Site

San Isidro, 27, Peru
Research Site

Gdynia, 81-519, Poland
Research Site

Lodz, 93-513, Poland
Research Site

Szczecin, 70-111, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Warsaw, 04-141, Poland
Research Site

Floreşti, 407280, Romania
Research Site

Goyang-si, 10408, South Korea
Research Site

Seongnam-si, 13620, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Suwon, 16499, South Korea
Research Site

Córdoba, 14004, Spain
Research Site

Madrid, 28033, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28040, Spain
Research Site

Madrid, 28041, Spain
Research Site

Terrassa(Barcelona), 08221, Spain
Research Site

Vigo, 36312, Spain
Research Site

Adana, 1260, Turkey (Türkiye)
Research Site

Ankara, 06230, Turkey (Türkiye)
Research Site

Ankara, 06490, Turkey (Türkiye)
Research Site

Istanbul, 34093, Turkey (Türkiye)
Research Site

Istanbul, 34384, Turkey (Türkiye)
Research Site

Izmir, 35100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.